ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting
Retrieved on:
Tuesday, May 16, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Abstract, Antigen, CRISPR, Gene, Intrinsic termination, PTPN2, Ovarian cancer, Integrated circuit, PSMA, Kidney cancer, Therapeutic index, CA9, Pharmacokinetics, FAS, Renal cell carcinoma, CAR, ICT, Patient, Treatment, TME, Cell, Canadian Aviation Regulations, American Society of Gene and Cell Therapy, Safety, Tumor microenvironment, Society, Synthetic biology, Pharmaceutical industry, Vaccine, Flour
The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.
Key Points:
- The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.
- AB-2100 is ArsenalBio’s second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
- The following abstracts will be presented as an oral abstract session and three posters during the ASGCT annual meeting.
- The SPA platform allows tuning of T cell biology to engineer T cell therapies with increased antitumor potency and cellular persistence.